Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s00262-017-2095-7, but it redirected us to https://link.springer.com/article/10.1007/s00262-017-2095-7. The analysis below is for the second page.

Title[redir]:
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors | Cancer Immunology, Immunotherapy
Description:
A substantial body of evidence suggests the existence of MUC1-specific antibodies and cytotoxic T cell activities in pancreatic cancer patients. However, tumor-induced immunosuppression renders these responses ineffective. The current study explores a novel therapeutic combination wherein tumor-bearing hosts can be immunologically primed with their own antigen, through opsonization with a tumor antigen-targeted antibody, mAb-AR20.5. We evaluated the efficacy of immunization with this antibody in combination with PolyICLC and anti-PD-L1. The therapeutic combination of mAb-AR20.5 + anti-PD-L1 + PolyICLC induced rejection of human MUC1 expressing tumors and provided a long-lasting, MUC1-specific cellular immune response, which could be adoptively transferred and shown to provide protection against tumor challenge in human MUC1 transgenic (MUC.Tg) mice. Furthermore, antibody depletion studies revealed that CD8 cells were effectors for the MUC1-specific immune response generated by the mAb-AR20.5 + anti-PD-L1 + PolyICLC combination. Multichromatic flow cytometry data analysis demonstrated a significant increase over time in circulating, activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in mAb-AR20.5 + anti-PD-L1 + PolyICLC combination-treated, tumor-bearing mice, as compared to saline-treated control counterparts. Our study provides a proof of principle that an effective and long-lasting anti-tumor cellular immunity can be achieved in pancreatic tumor-bearing hosts against their own antigen (MUC1), which can be further potentiated using a vaccine adjuvant and an immune checkpoint inhibitor.

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 8,426,336 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We can't tell how the site generates income.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

pubmed, article, cancer, google, scholar, cas, cells, central, pancreatic, tumor, muc, immune, immunol, human, immunity, res, cell, polyiclc, antibody, combination, antipdl, mice, gamma, mabar, hollingsworth, patients, clin, immunotherapy, muctg, tumors, schultes, mucspecific, access, delta, tcell, immunother, blockade, usa, privacy, cookies, content, immunology, responses, dendritic, vaccine, lymphocytes, type, therapy, data, publish,

Topics {✒️}

5 + anti-pd-l1 + polyiclc induced rejection 5 + anti-pd-l1 + polyiclc combination-treated granulocyte-macrophage colony-stimulating factor month download article/chapter anti-pd-1/pd-l1 therapy muc1-anti-muc1 immune complexes 5 + anti-pd-l1 + polyiclc combination anti-pd-l1 antibody ige antibody-dependent surveillance pd-1/pd-l1 blockade anti-muc1 monoclonal antibody anti-muc1 antibody as1402 listeria monocytogenes-expressing mesothelin immunotherapy t-cell function tumor-induced immunosuppression renders saline-treated control counterparts tumor-selective monoclonal antibody tumor antigen-targeted antibody muc1-specific tumor immunity human leukocyte antigen–antigen pancreatic tumor-bearing hosts anti-pd-l1 cd3+cd4−cd8− cd3+ cd4−cd8− article cancer immunology cellular antitumor immunity full article pdf t-cell exhaustion antitumor activity mediated vaccines immune complexes diaz la jr muc1-specific antibodies alpha-galactosylceramide-loaded tumor-specific immunity privacy choices/manage cookies human muc1 transgenic mhc class tumor cell type tlr3 ligand poly tumor-bearing hosts related subjects immune checkpoint blockade polyinosinic-polycytidylic acid invariant natural killer muc1 transgenic mice immune checkpoint inhibitor prevent immune decline cd19 antibodies assessed article mehla tumor-bearing mice

Questions {❓}

  • D’Acquisto F, Crompton T (2011) CD3+ CD4−CD8−(double negative) T cells: saviours or villains of the immune response?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors
         description:A substantial body of evidence suggests the existence of MUC1-specific antibodies and cytotoxic T cell activities in pancreatic cancer patients. However, tumor-induced immunosuppression renders these responses ineffective. The current study explores a novel therapeutic combination wherein tumor-bearing hosts can be immunologically primed with their own antigen, through opsonization with a tumor antigen-targeted antibody, mAb-AR20.5. We evaluated the efficacy of immunization with this antibody in combination with PolyICLC and anti-PD-L1. The therapeutic combination of mAb-AR20.5 + anti-PD-L1 + PolyICLC induced rejection of human MUC1 expressing tumors and provided a long-lasting, MUC1-specific cellular immune response, which could be adoptively transferred and shown to provide protection against tumor challenge in human MUC1 transgenic (MUC.Tg) mice. Furthermore, antibody depletion studies revealed that CD8 cells were effectors for the MUC1-specific immune response generated by the mAb-AR20.5 + anti-PD-L1 + PolyICLC combination. Multichromatic flow cytometry data analysis demonstrated a significant increase over time in circulating, activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in mAb-AR20.5 + anti-PD-L1 + PolyICLC combination-treated, tumor-bearing mice, as compared to saline-treated control counterparts. Our study provides a proof of principle that an effective and long-lasting anti-tumor cellular immunity can be achieved in pancreatic tumor-bearing hosts against their own antigen (MUC1), which can be further potentiated using a vaccine adjuvant and an immune checkpoint inhibitor.
         datePublished:2017-12-04T00:00:00Z
         dateModified:2017-12-04T00:00:00Z
         pageStart:445
         pageEnd:457
         sameAs:https://doi.org/10.1007/s00262-017-2095-7
         keywords:
            mAb-AR20.5 antibody
            PolyICLC
            Anti-PD-L1
            CD8 T cells
            MUC1
            Pancreatic cancer
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig6_HTML.jpg
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:67
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Kamiya Mehla
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jarrod Tremayne
               affiliation:
                     name:Mercaptor Discoveries Inc
                     address:
                        name:Mercaptor Discoveries Inc, Novato, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James A. Grunkemeyer
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kelly A. O’Connell
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria M. Steele
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas C. Caffrey
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xinyi Zhu
               affiliation:
                     name:Shanghai Jiao Tong University School of Medicine
                     address:
                        name:Shanghai Jiao Tong University School of Medicine, Shanghai Shi, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fang Yu
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:Department of Biostatistics, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pankaj K. Singh
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Birgit C. Schultes
               affiliation:
                     name:Unum Therapeutics
                     address:
                        name:Unum Therapeutics, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ragupathy Madiyalakan
               affiliation:
                     name:OncoQuest Inc.
                     address:
                        name:OncoQuest Inc., Edmonton, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christopher F. Nicodemus
               affiliation:
                     name:AIT Strategies
                     address:
                        name:AIT Strategies, Franconia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael A. Hollingsworth
               affiliation:
                     name:University of Nebraska Medical Center
                     address:
                        name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors
      description:A substantial body of evidence suggests the existence of MUC1-specific antibodies and cytotoxic T cell activities in pancreatic cancer patients. However, tumor-induced immunosuppression renders these responses ineffective. The current study explores a novel therapeutic combination wherein tumor-bearing hosts can be immunologically primed with their own antigen, through opsonization with a tumor antigen-targeted antibody, mAb-AR20.5. We evaluated the efficacy of immunization with this antibody in combination with PolyICLC and anti-PD-L1. The therapeutic combination of mAb-AR20.5 + anti-PD-L1 + PolyICLC induced rejection of human MUC1 expressing tumors and provided a long-lasting, MUC1-specific cellular immune response, which could be adoptively transferred and shown to provide protection against tumor challenge in human MUC1 transgenic (MUC.Tg) mice. Furthermore, antibody depletion studies revealed that CD8 cells were effectors for the MUC1-specific immune response generated by the mAb-AR20.5 + anti-PD-L1 + PolyICLC combination. Multichromatic flow cytometry data analysis demonstrated a significant increase over time in circulating, activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in mAb-AR20.5 + anti-PD-L1 + PolyICLC combination-treated, tumor-bearing mice, as compared to saline-treated control counterparts. Our study provides a proof of principle that an effective and long-lasting anti-tumor cellular immunity can be achieved in pancreatic tumor-bearing hosts against their own antigen (MUC1), which can be further potentiated using a vaccine adjuvant and an immune checkpoint inhibitor.
      datePublished:2017-12-04T00:00:00Z
      dateModified:2017-12-04T00:00:00Z
      pageStart:445
      pageEnd:457
      sameAs:https://doi.org/10.1007/s00262-017-2095-7
      keywords:
         mAb-AR20.5 antibody
         PolyICLC
         Anti-PD-L1
         CD8 T cells
         MUC1
         Pancreatic cancer
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-017-2095-7/MediaObjects/262_2017_2095_Fig6_HTML.jpg
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:67
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Kamiya Mehla
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jarrod Tremayne
            affiliation:
                  name:Mercaptor Discoveries Inc
                  address:
                     name:Mercaptor Discoveries Inc, Novato, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James A. Grunkemeyer
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kelly A. O’Connell
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria M. Steele
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas C. Caffrey
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xinyi Zhu
            affiliation:
                  name:Shanghai Jiao Tong University School of Medicine
                  address:
                     name:Shanghai Jiao Tong University School of Medicine, Shanghai Shi, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fang Yu
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:Department of Biostatistics, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pankaj K. Singh
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Birgit C. Schultes
            affiliation:
                  name:Unum Therapeutics
                  address:
                     name:Unum Therapeutics, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ragupathy Madiyalakan
            affiliation:
                  name:OncoQuest Inc.
                  address:
                     name:OncoQuest Inc., Edmonton, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christopher F. Nicodemus
            affiliation:
                  name:AIT Strategies
                  address:
                     name:AIT Strategies, Franconia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael A. Hollingsworth
            affiliation:
                  name:University of Nebraska Medical Center
                  address:
                     name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:67
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:Mercaptor Discoveries Inc
      address:
         name:Mercaptor Discoveries Inc, Novato, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:Shanghai Jiao Tong University School of Medicine
      address:
         name:Shanghai Jiao Tong University School of Medicine, Shanghai Shi, China
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:Department of Biostatistics, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
      name:Unum Therapeutics
      address:
         name:Unum Therapeutics, Boston, USA
         type:PostalAddress
      name:OncoQuest Inc.
      address:
         name:OncoQuest Inc., Edmonton, Canada
         type:PostalAddress
      name:AIT Strategies
      address:
         name:AIT Strategies, Franconia, USA
         type:PostalAddress
      name:University of Nebraska Medical Center
      address:
         name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Kamiya Mehla
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Jarrod Tremayne
      affiliation:
            name:Mercaptor Discoveries Inc
            address:
               name:Mercaptor Discoveries Inc, Novato, USA
               type:PostalAddress
            type:Organization
      name:James A. Grunkemeyer
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Kelly A. O’Connell
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Maria M. Steele
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Thomas C. Caffrey
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Xinyi Zhu
      affiliation:
            name:Shanghai Jiao Tong University School of Medicine
            address:
               name:Shanghai Jiao Tong University School of Medicine, Shanghai Shi, China
               type:PostalAddress
            type:Organization
      name:Fang Yu
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:Department of Biostatistics, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Pankaj K. Singh
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      name:Birgit C. Schultes
      affiliation:
            name:Unum Therapeutics
            address:
               name:Unum Therapeutics, Boston, USA
               type:PostalAddress
            type:Organization
      name:Ragupathy Madiyalakan
      affiliation:
            name:OncoQuest Inc.
            address:
               name:OncoQuest Inc., Edmonton, Canada
               type:PostalAddress
            type:Organization
      name:Christopher F. Nicodemus
      affiliation:
            name:AIT Strategies
            address:
               name:AIT Strategies, Franconia, USA
               type:PostalAddress
            type:Organization
      name:Michael A. Hollingsworth
      affiliation:
            name:University of Nebraska Medical Center
            address:
               name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
      name:Mercaptor Discoveries Inc, Novato, USA
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
      name:Shanghai Jiao Tong University School of Medicine, Shanghai Shi, China
      name:Department of Biostatistics, University of Nebraska Medical Center, Omaha, USA
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
      name:Unum Therapeutics, Boston, USA
      name:OncoQuest Inc., Edmonton, Canada
      name:AIT Strategies, Franconia, USA
      name:The Eppley Institute for Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(265)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

6.1s.